Clinical Trial Update: Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating olaparib in combination with pembrolizumab for advanced uveal/ocular melanoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Melanoma
• Uveal Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Uveal Melanoma, Ocular Melanoma | Phase 2 | Status: RECRUITING